Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson cancer center (MDACC).

被引：0
|
作者：
Jabbour, E
Cortes, J
Talpaz, M
Jones, D
O'Brien, S
Nicaise, C
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1091
引用
收藏
页码：318A / 318A
页数：1
相关论文
共 50 条
  • [1] Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib.
    Quintas-Cardama, A.
    Kantarjian, H.
    Jones, D.
    Talpaz, M.
    Jabbour, E.
    O'Brien, S.
    Luthra, R.
    Wierda, W.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [2] Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinill-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph plus ALL).
    Shah, N
    Sawyers, CL
    Kantarjian, HMM
    Donato, N
    Nicoll, J
    Cortes, J
    Paquette, R
    Huang, F
    Clark, E
    Talpaz, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 565S - 565S
  • [3] ASSESSMENT OF THE RESULT OF BCR-ABL MUTATION ANALYSIS IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS
    Demircioglu, S.
    Balasar, M.
    Yildirim, M.
    LEUKEMIA RESEARCH, 2016, 49 : S40 - S40
  • [4] Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients: Impact and fate of imatinib-resistant clones in dasatinib-treated patients.
    Branford, S
    Hughes, T
    Nicoll, J
    Paquette, R
    Bleickardt, E
    Sawyers, C
    Shah, N
    BLOOD, 2005, 106 (11) : 132A - 132A
  • [5] BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Kim, D.
    Saglio, G.
    Martinelli, G.
    Shou, Y.
    Stein, A. M.
    Woodman, R. C.
    Kantarjian, H.
    Hughes, T. P.
    Radich, J. P.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Increase of BCR-ABL/ABL Ratio That Corresponds to BCR-ABL Mutation Detection In Chronic Myeloid Leukemia (CML) Patients Treated by Imatinib (IM)
    Tsaur, Grigory
    Popov, Alexander
    Ivanova, Anna
    Yakovleva, Yulia
    Riger, Tatyana
    Plekhanova, Olga
    Ivanets, Yulia
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    FASEB JOURNAL, 2011, 25
  • [7] IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
    Tiribelli, M.
    Latagliata, R.
    Breccia, M.
    Luciano, L.
    Castagnetti, F.
    Gozzini, A.
    Cambrin, G. Rege
    Annunziata, M.
    Stagno, F.
    Pregno, P.
    Albano, F.
    Abruzzese, F.
    Musto, P.
    Sora, F.
    Ferrero, D.
    Montefusco, E.
    Cavazzini, F.
    Binotto, G.
    Fanin, R.
    Pane, F.
    Rosti, G.
    Santini, V.
    Fava, C.
    Alimena, G.
    Vigneri, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 347 - 347
  • [8] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
    Hasanova, Aypara
    Asadov, Chingiz
    Karimova, Nigar
    Shirinova, Aytan
    Aliyeva, Gunay
    Alimirzoyeva, Zohra
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [9] BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO IMATINIB THERAPY
    Tikhonova, V.
    Misyurina, E.
    Kesaeva, L.
    Finashutina, Y.
    Krutov, A.
    Aksenova, E.
    Soldatova, I.
    Soldatkina, O.
    Ivanova, V.
    Novitskaya, N.
    Arshanskaya, E.
    Lazarev, I.
    Volkova, M.
    Pospelova, T.
    Konstantinova, T.
    Vysotskaya, L.
    Voloditcheva, E.
    Lapin, V.
    Davydkin, I.
    Turkina, A.
    Kolosheinova, T.
    Goryacheva, S.
    Chelysheva, E.
    Pristupa, A.
    Golubenko, R.
    Gavrilova, L.
    Volkova, S.
    Kuchma, G.
    Ovsyannikova, E.
    Zaklyakova, L.
    Kaplanov, K.
    Klitochenko, T.
    Misyurin, A.
    HAEMATOLOGICA, 2013, 98 : 548 - 548
  • [10] A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002.
    Talpaz, M
    Kantarjian, HM
    Paquette, R
    Shah, N
    Cortes, J
    Nicoll, J
    Bai, SA
    Huang, F
    Decillis, AP
    Sawyers, CL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 564S - 564S
12345